Takeda Pharmaceutical Co Ltd
TSE:4502
Takeda Pharmaceutical Co Ltd
TSE:4502
Price:
4 143 JPY
-0.24%
Market Closed
Updated:
May 2, 2024
P/E
Price to Earnings
Price to Earnings
36.5
Current
23.2
Median
22.9
Industry
Higher
than median
Higher
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=36.5
Market Cap
/
6.5T
Net Income
178.2B
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| JP |
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
6.5T JPY | 36.5 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 347 888.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
737.4B USD | 140.7 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 47.8 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | -15 783.5 | |
| JP |
|
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | 9 733.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
363.9B USD | 9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
326.1B USD | 141.4 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
188.7B GBP | 39.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182B CHF | 13.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
175.9B CHF | 15.3 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
46.8
2-Years Forward
P/E
26.4
3-Years Forward
P/E
21.5
You don't have any saved screeners yet
